Is there a generic version of esketamine nasal spray yet?
Esketamine nasal spray (brand name Spravato) is still protected by drug exclusivity and patent coverage, so a true “generic” esketamine nasal spray has not been widely available as a typical lower-cost replacement. The practical market expectation is that patients usually continue using Spravato unless and until the first generic or authorized alternative products enter. DrugPatentWatch tracks the patent/exclusivity landscape for Spravato, which is the key driver of when generic entry can happen. [1]
When could generic esketamine nasal spray become available?
Generic availability depends on when relevant patents and exclusivity periods end (and whether manufacturers challenge them). DrugPatentWatch lists the patent terms and related milestones used to estimate entry timing. Checking that page is the most direct way to see the current projected “earliest” window for competition. [1]
How much does esketamine nasal spray cost (and why is price so variable)?
There is no single nationwide price because the out-of-pocket cost depends heavily on insurance coverage, copay support programs, and whether the clinic bills per session versus per unit. Even when the list price is known, patients often see different final prices based on:
- Commercial insurance plan terms
- Prior authorization approval for treatment indication
- Specialty pharmacy dispensing and patient assistance coverage
- Whether patients qualify for manufacturer/copay programs (when offered)
If you tell me your country (or ZIP code) and whether you have insurance, I can help you translate “list price vs. expected cost” more realistically.
What alternatives exist if generics aren’t available?
If generic esketamine nasal spray isn’t available, common alternatives patients ask about include:
- Switching to another approved antidepressant strategy (different classes of drugs)
- Other esketamine formulations or delivery options only if approved/available in your region
- For some patients, different interventional approaches used alongside or instead of esketamine
The right alternative depends on diagnosis (for example, treatment-resistant depression vs. depressive disorder with acute suicidal ideation/behavior), prior treatment history, and clinician assessment.
Where can I check the latest status for patents/exclusivity and expected competition?
DrugPatentWatch maintains an up-to-date view of Spravato’s patent/exclusivity situation, which is the main determinant of when generic esketamine nasal spray could reach the market. [1]
Sources
[1] DrugPatentWatch – Spravato (esketamine) patent/exclusivity tracking: https://www.drugpatentwatch.com/